会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
    • 使用天冬氨酰蛋白酶抑制剂治疗神经变性疾病的方法
    • US07119105B2
    • 2006-10-10
    • US10774262
    • 2004-02-05
    • Jonathan A. EllmanGary LynchIrwin D. KuntzXiaoning BiChristina E. LeeA. Geoffrey SkillmanTasir Haque
    • Jonathan A. EllmanGary LynchIrwin D. KuntzXiaoning BiChristina E. LeeA. Geoffrey SkillmanTasir Haque
    • A99Z99/00
    • C07D209/48A61K31/36A61K31/4035A61K31/423A61K31/445A61K31/4465A61K31/4525A61K31/454C07D263/58C07D317/58C07D317/60C07D317/62C07D405/12C07D413/12C07D413/14
    • The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (τ-protein); and (iv) methods for treating neurodegenerative diseases. For instance, in one embodiment, the present invention provides a method for modulating the processing of an amyloid precursor protein (APP), the method comprising contacting a composition containing the APP with an aspartyl protease inhibitor having the formula: wherein: R1, R2 and R3 are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and R5 and R6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R5 and R6 and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within the fused ring system.
    • 本发明涉及()非肽天冬氨酰蛋白酶抑制剂; (ii)调节淀粉样蛋白前体蛋白(APP)的加工的方法; (iii)调节tau蛋白(tau蛋白)的加工的方法; 和(iv)治疗神经变性疾病的方法。 例如,在一个实施方案中,本发明提供了调节淀粉样蛋白前体蛋白(APP)的加工的方法,所述方法包括将含有APP的组合物与具有下式的天冬氨酰蛋白酶抑制剂接触:其中: 1,R 2和R 3是独立地选自烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,芳氧基烷基 取代的芳氧基烷基,杂芳基,取代的杂芳基,杂芳基烷基,取代的杂芳基烷基,杂环,取代的杂环,杂环烷基和取代的杂环烷基; R 5和R 6独立地选自氢,卤素,烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,芳氧基烷基和取代的 芳氧基烷基; 或R 5和R 6和它们所连接的碳原子连接形成任选取代的碳环或杂环稠环体系,其具有总共9或10环 稠环体系内的原子。